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In 2017, there are 425 million patients 
living with diabetes in the world. This figure is 
estimated to increase by 45% or the 
equivalent of 629 million patients by 2045. 
Cardiovascular and kidney complications are 
the leading cause of death for diabetic patients 
in the world. Indonesia ranked 6th out of ten 
countries with the highest number of diabetes 
patients, which is 10.3 million patients in 
2017, and expected to increase to 16.7 million 
patients in 2045.[1]  
 Since 2014, a national social security 
system has been implemented in Indonesia, 
thus began the tiered referral era. In this 
condition, most diabetes mellitus patients will 
be treated at the first level of health facilities. 
Only when complications arise or things that 
require being referred to a specialist will be 
sent to a referral hospital. This causes most of 
the diagnosis and monitoring of therapy 
results to be carried out at the first health 
facility, which generally has limitations in 
medical facilities and personnel. For that, we 
need tools that can bridge the boundaries of 
medical facilities and personnel with the 
accuracy of diagnosis and monitoring therapy 
in diabetes mellitus patients.  
What is the guideline say? 
According to American Diabetes 
Association, diabetes may be diagnosed based 
on plasma glucose criteria, either the fasting 
plasma glucose (FPG) value or the 2-h plasma 
glucose (2-h PG) value during a 75-g oral 
glucose tolerance test (OGTT), or A1C 
criteria.[2] Guidelines for the management of 
diabetes mellitus in Indonesian adults issued 
by the Indonesian Society of Endocrinology 
(PERKENI) states that the diagnosis of 
diabetes mellitus includes examining fasting 
blood glucose ≥ 126 mg/dl, oral glucose 
tolerance test ≥ 200 mg/dl, or random blood 
glucose ≥ 200 mg/dl with classical diabetes 
symptoms, or HbA1C ≥ 6.5 % with 
standardized examination.  
HbA1C examination has been used as a 
standard for the diagnosis of diabetes mellitus 
for years. This examination has begun to be 
used as a definitive diagnosis of diabetes 
mellitus since the Diabetes Control and 
Complications Trial (DCCT) study showed an 
association between HbA1C levels and the risk 
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of complications from diabetes mellitus. 
Subsequent studies from United Kingdom 
Prospective Diabetes Study (UKPDS) also 
demonstrated an association between Hba1C 
levels and risk of complications, such as the 
level of HbA1c 10 % indicating a three times 
greater risk of retinopathy than the level of 
HbA1c 7.5%. [3]  
What kind of tools are available? 
Many methods have been developed to 
perform HbA1c assays based on differences in 
the structure between glycosylated and those 
that are not. The developed methods include 
ion-exchange chromategraphy, 
electrophoresis, boronated affinity 
chromatography, and immunoassay methods. 
The existence of these several methods 
implies challenges in standardizing HbA1C 
examinations. This standardization is needed 
to ensure that HbA1C results can be correlated 
with studies from DCCT and UKPDS that show 
an association between HbA1C levels and 
complications that can occur. For this reason, 
a standard HbA1C examination was created by 
the American Association for Clinical 
Chemistry (AACC), which implemented The 
National Glycohemoglobin Standardization 
Program (NGSP) to standardize HbA1C tests 
since 1996.[4] 
(HPLC) High-Performance Liquid 
Chromatography and electron spray mass 
spectrometry are some of the methodologies 
used as references for measuring HbA1c. Still, 
these two examinations require substantial 
costs, facilities, and infrastructure. This is, of 
course, a problem related to the financing that 
must be issued if this examination is a routine 




What are the options? 
In the last few months, HbA1c 
examination by Point of Care Testing (POCT) 
is developed in Indonesia. POCT is a method of 
examination performed outside the central 
laboratory using instruments. In diabetes 
mellitus patients, POCT is commonly used for 
blood glucose control such as glucometer 
examination. Currently, POCT checks are also 
being used to monitor HbA1C. The challenge 
that has been raised is the need for 
standardization with a tool that has been 
established as a definitive diagnosis. POCT for 
HbA1C examination has several advantages 
such as the use of a practical tool in the sense 
that it can be used immediately without having 
much special preparation, results that can be 
seen in a short time, the use of fingerstick 
instead of venous blood so that the patient will 
be more comfortable.[5]  
Several studies report improved 
outcomes from the implementation of POCT to 
use in the outpatient and inpatient setting, 
both in the form of medical outcomes such as 
enhanced disease control, operational 
outcomes such as decreased length of stay, and 
financial outcomes (cost control).[6] In his 
review article, Schnell concluded that 
examining HbA1 utilizing POCT would 
improve compliance with the implementation 
of HbA1c examination recommendations as a 
method of monitoring blood glucose control, 
improving clinical outcomes, and improving 
patient education and motivation, improve the 
quality of life of patients, also saving costs.[7] 
Most of the data above were obtained 
from patients who performed blood glucose 
control at the referral hospital. With the tiered 
referral system of the Sistem Jaminan Sosial 
Nasional currently in effect in Indonesia, the 
largest number of patients will be in primary 
health care. A diagnostic examination system 
and monitoring of therapeutic results are 
simple but high accuracy is needed.  A study is 
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needed to see how the accuracy and efficiency 
of the POCT examination for Hba1c used in 
primary health services in Indonesia so that it 
can be used as the basis for the wider use of 
POCT-HbA1C. 
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